Home Lab Services Guide Tests

BROWSE BY TEST NAME

Clear

Overview
ข้อมูลทั่วไป Specimen
ข้อมูลสิ่งส่งตรวจ Performance
ข้อมูลการทดสอบ Clinical & Interpretation
ข้อมูลทางคลินิก

Test Code (รหัสการทดสอบ):

090-81-2036

Order Name (ชื่อการทดสอบ):

Adalimumab Quantitative with Reflex to Antibody **

Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):

Blood/ Plain blood (Red top) 6 mL, 2 tubes

Turnaround Time (ระยะเวลารอผล):

14 days

Useful For (ประโยชน์การทดสอบ):

Therapeutic drug monitoring of adalimumab concentration and antibody levels, if appropriate.

Methodology (วิธีการทดสอบ):

Enzyme-Linked Immunosorbent Assay (ELISA)

Test List In Profile (การทดสอบใน Profile):

Adalimumab Level
(with auto-reflex to Antibody if the level result is 8.0 mcg/mL or less)

AliasesName (ชื่อเรียกอื่นๆ) :

TEST ID : ADALX

Test Code (รหัสการทดสอบ):

090-81-2036

Order Name (ชื่อการทดสอบ):

Adalimumab Quantitative with Reflex to Antibody **

Patient Preparation (การเตรียมตัวผู้ป่วย):

For 12 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7)

Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):

Blood/ Plain blood (Red top) 6 mL, 2 tubes

Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):

Serum, minimum volume 1 mL x 2 tubes

Sub Mission Container (ภาชนะส่งตรวจ):

Plastic tube

Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):

Heat-treated specimen: Reject

Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):

Serum Refrigerated or Frozen, 28 days

Test Code (รหัสการทดสอบ):

090-81-2036

Order Name (ชื่อการทดสอบ):

Adalimumab Quantitative with Reflex to Antibody **

Schedule (ตารางการทดสอบ):

N/A **Sent Out to MAYO, USA

Turnaround Time (ระยะเวลารอผล):

14 days

Performing Location (หน่วยงานที่ทำการทดสอบ):

MAYO Laboratory
Referral Lab Services, Laboratory Department 14162

Test Code (รหัสการทดสอบ):

090-81-2036

Order Name (ชื่อการทดสอบ):

Adalimumab Quantitative with Reflex to Antibody **

Clinical Information (ข้อมูลทางคลินิก):

Adalimumab, sold under the brand names Amjevita and Humira, is a US Food and Drug Administration-approved medication used to treat rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and chronic psoriasis, among others. It is usually self-administered as a subcutaneous injection every other week at a fixed dose of 40 mg in adults, although dosing can vary. Adalimumab is a tumor necrosis factor (TNF)-inhibiting, antiinflammatory, biologic medication. TNF-alpha normally binds to TNF-alpha receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNF-alpha, adalimumab can reduce the inflammatory response. Because TNF-alpha is also part of the immune system that protects the body from infection, treatment with adalimumab may increase the risk of infections. Treatment with adalimumab is effective in reducing disease activity, offers significant benefits in quality of life, and may have the potential to slow or halt the progression of the disease when given early. However, over 30% of patients fail to respond to anti-TNF-alpha therapy, and approximately 60% of patients who responded initially lose the response over time and require either drug dose-escalation or a switch to an alternative therapy in order to maintain response.

Reference Value (ค่าอ้างอิง):

ADALIMUMAB QUANTITATIVE: Limit of quantitation is 0.8 mcg/mL. Optimal therapeutic ranges are disease specific.
(if reflex) ADALIMUMAB ANTIBODY: <14.0 AU/mL

Clinical Reference (เอกสารอ้างอิง):